ERBB2 and breast cancer: Of a total of 3330 breast cancer patients, identification by molecular subtype (luminal [RH+ HER2], human epidermal growth factor receptor 2 HER2+ [RH+/− HER2+], triple negative [RH− HER2−], according to modified classification of the European Society of Medical Oncology [ESMO] [32]) was available in 2308 patients (69.3%).